| Role of Bruton’s tyrosine kinase in B cells and malignancies S Pal Singh, F Dammeijer, RW Hendriks Molecular cancer 17 (1), 57, 2018 | 635 | 2018 |
| The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes F Dammeijer, M van Gulijk, EE Mulder, M Lukkes, L Klaase, ... Cancer cell 38 (5), 685-700. e8, 2020 | 386 | 2020 |
| Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy F Dammeijer, LA Lievense, ME Kaijen-Lambers, M van Nimwegen, ... Cancer immunology research 5 (7), 535-546, 2017 | 134 | 2017 |
| Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets? A Huber, F Dammeijer, JGJV Aerts, H Vroman Frontiers in immunology 9, 2804, 2018 | 112 | 2018 |
| Combination strategies to optimize efficacy of dendritic cell-based immunotherapy M Van Gulijk, F Dammeijer, JGJV Aerts, H Vroman Frontiers in immunology 9, 2759, 2018 | 76 | 2018 |
| Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors F Dammeijer, SP Lau, CHJ van Eijck, SH van der Burg, JGJV Aerts Cytokine & growth factor reviews 36, 5-15, 2017 | 67 | 2017 |
| Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis F Dammeijer, LA Lievense, GDM Veerman, HC Hoogsteden, ... Journal of Clinical Oncology 34 (26), 3204-3212, 2016 | 55 | 2016 |
| Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model SP Lau, N van Montfoort, P Kinderman, M Lukkes, L Klaase, ... Journal for immunotherapy of cancer 8 (2), 2020 | 53 | 2020 |
| Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial CJ de Gooijer, V van der Noort, JA Stigt, P Baas, B Biesma, R Cornelissen, ... The Lancet Respiratory Medicine 9 (6), 585-592, 2021 | 41 | 2021 |
| PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance M van Gulijk, A van Krimpen, S Schetters, M Eterman, M van Elsas, ... Science Immunology 8 (83), eabn6173, 2023 | 25 | 2023 |
| Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy. Cancer Immunol. Res. 2017; 5: 535 … F Dammeijer, LA Lievense, ME Kaijen-Lambers, M Van Nimwegen, ... CIR-16-0309.[Abstract][CrossRef][Google Scholar], 0 | 25 | |
| Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma A van Krimpen, VIV Gerretsen, EEAP Mulder, M van Gulijk, ... Cancer Cell 40 (8), 798-799, 2022 | 23 | 2022 |
| Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response F Dammeijer, CJ De Gooijer, M van Gulijk, M Lukkes, L Klaase, ... EBioMedicine 64, 2021 | 18 | 2021 |
| Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future CM Steendam, F Dammeijer, JGJV Aerts, R Cornelissen Immunotherapy 9 (6), 507-520, 2017 | 18 | 2017 |
| Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy F Dammeijer, M van Gulijk, L Klaase, M van Nimwegen, R Bouzid, ... Molecular Cancer Therapeutics 21 (9), 1393-1405, 2022 | 5 | 2022 |
| Combination of PD‐1/PD‐L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma M van Gulijk, B Belderbos, D Dumoulin, R Cornelissen, K Bezemer, ... International Journal of Cancer 152 (7), 1438-1443, 2023 | 4 | 2023 |
| Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition M Zhao, L Li, CH Kiernan, MD Castro Eiro, F Dammeijer, M van Meurs, ... Scientific Reports 13 (1), 15678, 2023 | 2 | 2023 |
| MA12. 09 Checkpoint inhibitors synergize with dendritic cell-therapy in pre-clinical models and mesothelioma patients R Belderbos, F Dammeijer, M Gulijk, M Lukkes, D Dumoulin, ... Journal of Thoracic Oncology 14 (10), S298-S299, 2019 | 2 | 2019 |
| Re: Comments on ‘High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and … L Cantini, F Pecci, F Dammeijer, JGJV Aerts, R Berardi European Journal of Cancer 153, 267-269, 2021 | 1 | 2021 |
| Efficient Synthesis of 3, 4-Disubstituted 7-Azaindoles Employing SEM as a Dual Protecting–Activating Group P Gyárfás, J Gerencsér, WS Wade, L Ürögdi, Z Novák, ST Meyer Synlett 30 (20), 2273-2278, 2019 | 1 | 2019 |
